Q-omics provides the consensus-scored LRCOL1 profile across patient tissues and cancer cell-line models. LRCOL1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LRCOL1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, LRCOL1 RNA expression shows 12,420 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, THCA, and KIRP as cancer lineages where LRCOL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRCOL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRCOL1 survival associations across molecular data types. LRCOL1 RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRCOL1 RNA expression–survival associations across cancer types. High LRCOL1 expression shows unfavorable associations in UVM, KIRC, LUSC and STAD, but favorable associations in HNSC and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LRCOL1 RNA expression.
This table summarizes LRCOL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LRCOL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRCOL1 shows lower tumor expression in LUAD, LIHC, LUSC, BRCA and CHOL and higher tumor expression in THCA. The THCA box plot shows higher LRCOL1 RNA expression in tumor versus normal tissue (log2 FC = +1.058, t-test p < 0.001).
This table shows molecular features associated with LRCOL1 in patient tissues and cancer cell lines. In patient samples, LRCOL1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, LRCOL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS.
